Inhibition of Macrophage Migration Inhibitory Factor Reduces Diabetic Nephropathy in Type II Diabetes Mice

Inflammation

Volumn 37, Issue 6, 2014, Pages 2020-2029

  Wang, Zhigang ^a   Wei, Meng ^a   Wang, Meng ^a   Chen, Lei ^a   Liu, Hua ^a   Ren, Yi ^a   Shi, Kehui ^a   Jiang, Hongli ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

diabetes; macrophage; macrophage inhibitory factor; nephropathy

Indexed keywords

3-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLEACETIC ACID METHYL ESTER; GLUCOSE BLOOD LEVEL; ISOMERASE; ISOXAZOLE DERIVATIVE; MACROPHAGE MIGRATION INHIBITION FACTOR; MIF PROTEIN, MOUSE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL CULTURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; INTRAMOLECULAR OXIDOREDUCTASES; ISOXAZOLES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED C57BL;

EID: 84937558875     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9934-x     Document Type: Article

References (41)

1. Al-Abed, Y., D. Dabideen, B. Aljabari, A. Valster, D. Messmer, M. Ochani, M. Tanovic, K. Ochani, M. Bacher, F. Nicoletti, C. Metz, V.A. Pavlov, E.J. Miller, and K.J. Tracey. 2005. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. The Journal of Biological Chemistry 280(44): 36541–36544.
2. Al-Abed, Y., and S. VanPatten. 2011. MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Medicinal Chemistry 3(1): 45–63.
3. Calandra, T., and T. Roger. 2003. Macrophage migration inhibitory factor: A regulator of innate immunity. Nature Reviews Immunology 3(10): 791–800.
4. Catania, J.M., G. Chen, and A.R. Parrish. 2007. Role of matrix metalloproteinases in renal pathophysiologies. American Journal of Physiology. Renal Physiology 292(3): F905–F911.
5. Cheng, Q., S.J. McKeown, L. Santos, F.S. Santiago, L.M. Khachigian, E.F. Morand, and M.J. Hickey. 2010. Macrophage migration inhibitory factor increases leukocyte–endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. Journal of Immunology 185(2): 1238–1247.
6. Chow, F., E. Ozols, D.J. Nikolic-Paterson, R.C. Atkins, and G.H. Tesch. 2004. Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury. Kidney International 65(1): 116–128.
7. de Jong, Y.P., A.C. Abadia-Molina, A.R. Satoskar, K. Clarke, S.T. Rietdijk, W.A. Faubion, E. Mizoguchi, C.N. Metz, M. Alsahli, T. ten Hove, A.C. Keates, J.B. Lubetsky, R.J. Farrell, P. Michetti, S.J. van Deventer, E. Lolis, J.R. David, A.K. Bhan, and C. Terhorst. 2001. Development of chronic colitis is dependent on the cytokine MIF. Nature Immunology 2(11): 1061–1066.
8. Duffield, J.S. 2003. The inflammatory macrophage: A story of Jekyll and Hyde. Clinical Science 104(1): 27–38.
9. Ejarque-Ortiz, A., M.G. Medina, J.M. Tusell, A.P. Perez-Gonzalez, J. Serratosa, and J. Saura. 2007. Upregulation of CCAAT/enhancer binding protein beta in activated astrocytes and microglia. Glia 55(2): 178–188.
10. Englen, M.D., Y.E. Valdez, N.M. Lehnert, and B.E. Lehnert. 1995. Granulocyte/macrophage colony-stimulating factor is expressed and secreted in cultures of murine L929 cells. Journal of Immunological Methods 184(2): 281–283.
11. Furuta, T., T. Saito, T. Ootaka, J. Soma, K. Obara, K. Abe, and K. Yoshinaga. 1993. The role of macrophages in diabetic glomerulosclerosis. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation 21(5): 480–485.
12. Greka, A., and P. Mundel. 2012. Cell biology and pathology of podocytes. Annual Review of Physiology 74: 299–323.
13. Herder, C., H. Kolb, W. Koenig, B. Haastert, S. Muller-Scholze, W. Rathmann, R. Holle, B. Thorand, and H.E. Wichmann. 2006. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: Results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 29(2): 368–371.
14. Hirata, K., K. Shikata, M. Matsuda, K. Akiyama, H. Sugimoto, M. Kushiro, and H. Makino. 1998. Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 41(2): 185–192.
15. Ikezumi, Y., T. Suzuki, T. Karasawa, H. Kawachi, D.J. Nikolic-Paterson, and M. Uchiyama. 2008. Activated macrophages down-regulate podocyte nephrin and podocin expression via stress-activated protein kinases. Biochemical and Biophysical Research Communications 376(4): 706–711.
16. Impellizzeri, D., E. Esposito, J. Attley, and S. Cuzzocrea. 2014. Targeting inflammation: New therapeutic approaches in chronic kidney disease (CKD). Pharmacological Research: The Official Journal of the Italian Pharmacological Society 81C: 91–102.
17. Kigerl, K.A., W. Lai, S. Rivest, R.P. Hart, A.R. Satoskar, and P.G. Popovich. 2007. Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. Journal of Neurochemistry 102(1): 37–50.
18. Lan, H.Y., and A.C. Chung. 2012. TGF-beta/Smad signaling in kidney disease. Seminars in Nephrology 32(3): 236–243.
19. Leung, J.C., L.Y. Chan, A.W. Tsang, E.W. Liu, M.F. Lam, S.C. Tang, and K.N. Lai. 2004. Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association—European Renal Association 19(8): 1976–1985.
20. Lubetsky, J.B., A. Dios, J. Han, B. Aljabari, B. Ruzsicska, R. Mitchell, E. Lolis, and Y. Al-Abed. 2002. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. The Journal of Biological Chemistry 277(28): 24976–24982.
21. Malorny, U., M. Goebeler, J. Gutwald, J. Roth, and C. Sorg. 1990. Differences in migration inhibitory factor production by C57Bl/6 and BALB/c mice in allergic and irritant contact dermatitis. International Archives of Allergy and Applied Immunology 92(4): 356–360.
22. Meyer-Siegler, K.L., K.A. Iczkowski, L. Leng, R. Bucala, and P.L. Vera. 2006. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. Journal of Immunology 177(12): 8730–8739.
23. Misseri, R., D.R. Meldrum, C.A. Dinarello, P. Dagher, K.L. Hile, R.C. Rink, and K.K. Meldrum. 2005. TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. American Journal of Physiology. Renal Physiology 288(2): F406–F411.
24. Mora, C., and J.F. Navarro. 2006. Inflammation and diabetic nephropathy. Current Diabetes Reports 6(6): 463–468.
25. Morishita, Y., M. Watanabe, E. Nakazawa, K. Ishibashi, and E. Kusano. 2011. The interaction of LFA-1 on mononuclear cells and ICAM-1 on tubular epithelial cells accelerates TGF-beta1-induced renal epithelial–mesenchymal transition. PLoS ONE 6(8): e23267.
26. Mundel, P., J. Reiser, A. Zuniga Mejia Borja, H. Pavenstadt, G.R. Davidson, W. Kriz, and R. Zeller. 1997. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Experimental Cell Research 236(1): 248–258.
27. Navarro-Gonzalez, J.F., and C. Mora-Fernandez. 2008. The role of inflammatory cytokines in diabetic nephropathy. Journal of the American Society of Nephrology: JASN 19(3): 433–442.
28. Okada, H., T.M. Danoff, R. Kalluri, and E.G. Neilson. 1997. Early role of Fsp1 in epithelial–mesenchymal transformation. The American Journal of Physiology 273(4 Pt 2): F563–F574.
29. Roger, T., C. Froidevaux, C. Martin, and T. Calandra. 2003. Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). Journal of Endotoxin Research 9(2): 119–123.
30. Ruster, C., and G. Wolf. 2008. The role of chemokines and chemokine receptors in diabetic nephropathy. Frontiers in Bioscience: A Journal and Virtual Library 13: 944–955.
31. Sanchez-Nino, M.D., A.B. Sanz, P. Ihalmo, M. Lassila, H. Holthofer, S. Mezzano, C. Aros, P.H. Groop, M.A. Saleem, P.W. Mathieson, R. Langham, M. Kretzler, V. Nair, K.V. Lemley, R.G. Nelson, E. Mervaala, D. Mattinzoli, M.P. Rastaldi, M. Ruiz-Ortega, J.L. Martin-Ventura, J. Egido, and A. Ortiz. 2009. The MIF receptor CD74 in diabetic podocyte injury. Journal of the American Society of Nephrology: JASN 20(2): 353–362.
32. Sanchez-Zamora, Y.I., and M. Rodriguez-Sosa. 2014. The role of MIF in type 1 and type 2 diabetes mellitus. Journal of Diabetes Research 2014: 804519.
33. Sasaki, S., J. Nishihira, T. Ishibashi, Y. Yamasaki, K. Obikane, M. Echigoya, Y. Sado, Y. Ninomiya, and K. Kobayashi. 2004. Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney International 65(2): 469–481.
34. Shyu, L.Y., T.M. Yeh, H.H. Chang, D.P. Lin, Y.H. Teng, L.C. Chen, and H.H. Lee. 2012. Macrophage migration inhibitory factor induces ICAM-1and thrombomobulin expression in vitro. Thrombosis Research 129(1): 43–49.
35. Tashimo, A., Y. Mitamura, S. Nagai, Y. Nakamura, K. Ohtsuka, Y. Mizue, and J. Nishihira. 2004. Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy. Diabetic Medicine: A Journal of the British Diabetic Association 21(12): 1292–1297.
36. Tuttle, K.R. 2005. Linking metabolism and immunology: Diabetic nephropathy is an inflammatory disease. Journal of the American Society of Nephrology: JASN 16(6): 1537–1538.
37. Watanabe, T., N.H. Tomioka, M. Doshi, S. Watanabe, M. Tsuchiya, and M. Hosoyamada. 2013. Macrophage migration inhibitory factor is a possible candidate for the induction of microalbuminuria in diabetic db/db mice. Biological & Pharmaceutical Bulletin 36(5): 741–747.
38. White, D.A., Y. Su, P. Kanellakis, H. Kiriazis, E.F. Morand, R. Bucala, A.M. Dart, X.M. Gao, and X.J. Du. 2014. Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction. Journal of Molecular and Cellular Cardiology 69: 32–42.
39. Wolf, G., G.S. Kuncio, M.J. Sun, and E.G. Neilson. 1991. Expression of homeobox genes in a proximal tubular cell line derived from adult mice. Kidney International 39(5): 1027–1033.
40. You, H., T. Gao, T.K. Cooper, W. Brian Reeves, and A.S. Awad. 2013. Macrophages directly mediate diabetic renal injury. American Journal of Physiology. Renal Physiology 305(12): F1719–F1727.
41. Zamboni, D.S., and M. Rabinovitch. 2003. Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages. Infection and Immunity 71(3): 1225–1233.